Um die volle Funktionalität der Webseite nutzen zu können, müssen Sie JavaScript in ihrem Browser aktivieren.

DAX23.284,68+0,90 %

Gold3.368,750,00 %

Öl (Brent)77,19-2,12 %

Dow Jones42.187,12+0,95 %

US Tech 10021.627,99+0,71 %

EUR/USD1,15225+0,23 %

Top 15 der gesamten Suchanfragen der letzten 7 Tage

Login

Cadrenal Therapeutics Aktie

Aktie

ISIN: US1276362076 SYM: CVKD Land Flagge US

USA

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

12,350

USD

-7,77 %

-1,040 USD

Letzter Kurs 21.06.25 Nasdaq

Cadrenal Therapeutics Aktie kaufen

Geldkurs

20.06.25

12,350

USD

100 STK

Briefkurs

20.06.25

12,520

USD

100 STK

BEI SMARTBROKER+ HANDELN

Handeln über unsere
Partner-Broker

Brokerize

Neueste Nachrichten

Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients 12.06.25 · Business Wire (engl.) · Cadrenal Therapeutics
Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025 04.06.25 · Business Wire (engl.) · Cadrenal Therapeutics
Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness 15.05.25 · Business Wire (engl.) · Cadrenal Therapeutics
Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update 08.05.25 · Business Wire (engl.) · Cadrenal Therapeutics
Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq 17.04.25 · Business Wire (engl.) · Nasdaq Inc. Aktie
Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences 03.04.25 · Business Wire (engl.) · Cadrenal Therapeutics
Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin 13.03.25 · Business Wire (engl.) · Cadrenal Therapeutics
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3 LVAD 04.03.25 · Business Wire (engl.) · Cadrenal Therapeutics
Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin 06.02.25 · Business Wire (engl.) · Cadrenal Therapeutics
Cadrenal Therapeutics to Present at BIO CEO & Investor Conference 05.02.25 · Business Wire (engl.) · Cadrenal Therapeutics
Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 09.01.25 · Business Wire (engl.) · Cadrenal Therapeutics
Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications 31.12.24 · Business Wire (engl.) · Cadrenal Therapeutics

1
2

Meistgelesen

30 Tage
12 Monate

Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025 104 Leser
Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients 100 Leser

Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing 156 Leser
Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq 124 Leser
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of ... 124 Leser
Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update 108 Leser
Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on ... 108 Leser
Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan ... 108 Leser
Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025 104 Leser
Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences 104 Leser
Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of ... 104 Leser
Cadrenal Therapeutics to Present at BIO CEO & Investor Conference 104 Leser